News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics gets Notice of Allowance for a new US patent for a combination therapy with Aladote

December 1, 2021

Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that the US Patent Office (USPTO) has issued a Notice of Allowance for a new patent covering a combination treatment with the company’s clinical candidate drug Aladote® (calmangafodipir) and N-acetylcysteine ​​(NAC). The new patent further improves the unique value proposition of the Aladote franchise and provides patent protection until year 2037 in the US, before a potential extension.

The new patent covers a combination treatment with NAC and Aladote for “late presenters”, i e patients that started treatment with NAC and calmangafodipir 8 hours or later after an overdose of paracetamol. A potential combination product is also covered by the patent.

“We are very pleased that the patent for this combination treatment of Aladote and NAC will be granted, which further strengthens our robust calmangafodipir patent portfolio that amongst others includes a composition of matter patent with protection until year 2032 in US and EU ”, said Nicklas Westerholm, CEO, Egetis Therapeutics.

Aladote has been granted Orphan Drug Designation in the US and an application for ODD was submitted in Europe in Q1 2021. There is an ongoing dialogue with EMA on the appropriate indication for an ODD in the EU.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com